Abstract. The addition of polysorbate 20 (T20) is required to achieve “sink ” conditions during a dissolu-tion test for tablets with candesartan cilexetil (CC). Polysorbate 20 (0.35%–0.7%w/w) added to 0.05 mol/L of phosphate buffer pH 6.5 dramatically increased the apparent solubility of the drug from 0.8 μg/ml even to 353 μg/ml, while its effect in lower pH or in water was much smaller (20 μg/ml in pH 4.5). The increased concentration of phosphate salts (0.2 mol/l) at pH 6.5 in the presence of 0.7 % of polysorbate 20, resulted in further increase of candesartan cilexetil solubility to 620 μg/ml. The change of pH from 1.2 to 7.4 resulted in a 1.5-fold increase of the activation energy and, depending on temperature, 8–14-fold decrease of the...
Objective: The present study aims at development of solid dispersions (SD) of candesartan cilexetil ...
Objective The main objective of the present study is systematic development of solid dispersions of ...
The aim of present work was to develop a stable Cytarabine injectable formulation for the treatment ...
The main aim of our investigation was to enhance the dissolution of Candesartan Cilexetil, a prodrug...
Candesartan cilexetil is a poorly soluble antihypertensive agent with low bioavailability. It is a p...
To access publisher's full text version of this article click on the hyperlink belowThe poor aqueous...
<p>This article investigates the aqueous solubility of the poorly soluble drug candesartan cilexetil...
Development of solid dispersions of poorly water soluble drugs is one of the most widely used approa...
AbstractA simple, rapid, selective and reproducible reversed-phase high performance liquid chromatog...
Purpose: The individual and interaction effects of nature of binder (N), concentration of binder (C)...
Purpose: To comparatively evaluate the effect of two hydroxylpropyl methylcellulose (HPMC) molecular...
Purpose: To enhance the otherwise poor solubility and bioavailability of candesartan cilexetil (CDS)...
The solubility enhancement of poorly soluble compounds is an important task in pharmaceutical techno...
This article investigates enhancement Solubility is an important physicochemical factor affecting ab...
The effects of selected superdisintegrants on the dissolution behavior of several cationic drugs wit...
Objective: The present study aims at development of solid dispersions (SD) of candesartan cilexetil ...
Objective The main objective of the present study is systematic development of solid dispersions of ...
The aim of present work was to develop a stable Cytarabine injectable formulation for the treatment ...
The main aim of our investigation was to enhance the dissolution of Candesartan Cilexetil, a prodrug...
Candesartan cilexetil is a poorly soluble antihypertensive agent with low bioavailability. It is a p...
To access publisher's full text version of this article click on the hyperlink belowThe poor aqueous...
<p>This article investigates the aqueous solubility of the poorly soluble drug candesartan cilexetil...
Development of solid dispersions of poorly water soluble drugs is one of the most widely used approa...
AbstractA simple, rapid, selective and reproducible reversed-phase high performance liquid chromatog...
Purpose: The individual and interaction effects of nature of binder (N), concentration of binder (C)...
Purpose: To comparatively evaluate the effect of two hydroxylpropyl methylcellulose (HPMC) molecular...
Purpose: To enhance the otherwise poor solubility and bioavailability of candesartan cilexetil (CDS)...
The solubility enhancement of poorly soluble compounds is an important task in pharmaceutical techno...
This article investigates enhancement Solubility is an important physicochemical factor affecting ab...
The effects of selected superdisintegrants on the dissolution behavior of several cationic drugs wit...
Objective: The present study aims at development of solid dispersions (SD) of candesartan cilexetil ...
Objective The main objective of the present study is systematic development of solid dispersions of ...
The aim of present work was to develop a stable Cytarabine injectable formulation for the treatment ...